KRAS and neoplasm: The mechanisms underlying the enhanced radioresistance in KRAS-mutated tumours have been studied using colorectal cancer cell lines, which revealed that mutated KRAS isoforms activate EGFR and H-Ras, resulting in enhanced cellular radioresistance through PI3K/AKT signalling [66].